Cuprina Holdings (Cayman) Limited Overview
Pro stress-test →Cuprina Holdings is a biomedical and biotechnology company focused on the development and commercialization of products for the management of chronic wounds. The company manufactures and distributes medical grade sterile blowfly larvae bio-dressing products under the MEDIFLY brand, with pipeline products including collagen dressings using bullfrog collagen and medical leech-based treatments.
Strategic Profile
Pro stress-test →Cuprina characterizes itself as dedicated to chronic wound management, infertility-related products, cosmeceuticals and medical waste recycling, with activities spanning medical devices, biotherapeutic modalities like maggot and leech therapies, IVF media production, and collagen-based research. The company went public via IPO on April 10, 2025, raising $12 million at $4 per share on NASDAQ, though it faces operational and regulatory challenges as a micro-cap biotech.
Competitive Landscape
Pro stress-test →Comparable companies in the medical instruments and supplies sector include Retractable Technologies, Precision Optics, Nexgel Inc, Harvard Bioscience, and Bionano Genomics. Cuprina competes in the niche chronic wound management market with bio-therapeutic approaches (maggot therapy, leech therapy) against larger wound care players offering conventional dressings and advanced therapies.
Industry Context
Cuprina Holdings (Cayman) Limited operates in Biomedical & Biotechnology - Chronic Wound Management.
Key facts
Founded: 2025 · Headquarters: Singapore · Employees: 14 · Revenue: $39K (TTM) · Market cap: $5.3M